GLPG1690 + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Pulmonary Fibrosis
Conditions
Idiopathic Pulmonary Fibrosis
Trial Timeline
Nov 28, 2018 → Mar 30, 2021
NCT ID
NCT03711162About GLPG1690 + Placebo
GLPG1690 + Placebo is a phase 3 stage product being developed by Galapagos for Idiopathic Pulmonary Fibrosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03711162. Target conditions include Idiopathic Pulmonary Fibrosis.
What happened to similar drugs?
20 of 20 similar drugs in Idiopathic Pulmonary Fibrosis were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03798366 | Phase 2 | Completed |
| NCT03711162 | Phase 3 | Terminated |
| NCT03733444 | Phase 3 | Terminated |
Competing Products
20 competing products in Idiopathic Pulmonary Fibrosis